| Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.Lancet Diabetes Endocrinol | PMID 40318682无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis.Lupus | PMID 40322925PMC12141769 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial.Radiother Oncol | PMID 40324910无 PMCID | 2025-Jun | 0.95 | The trial is a randomized phase III study in human oncology (spinal metastases). However, the intervention is radiotherapy (esophagus-sparing vs. standard), not a drug-containing regimen. Furthermore, the co-primary endpoints are patient-reported dysphagia and ambulatory function, which are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS, RFS, TTP) or analyses based on Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the eligibility criteria for this cohort. | 待处理 |
| Bacterial Infections in Patients With Severe Alcohol-Associated Hepatitis: Drivers of Organ Failure and Mortality.Liver Int | PMID 40332100PMC12057653 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 部分完成 |
| EFFICACY AND SAFETY OF LIDOCAINE WITH CLONIDINE FOR MAXILLARY INFILTRATION ANESTHESIA IN PATIENTS WITH DIABETES MELLITUS TYPE 2: DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL.J Evid Based Dent Pract | PMID 40335197无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| ANTIPLAQUE AND ANTIGINGIVITIS EFFECTS OF A NOVEL ORAL CARE REGIMEN FEATURING STANNOUS FLUORIDE TOOTHPASTE, A UNIQUE TOOTHBRUSH, AND CETYLPYRIDINIUM CHLORIDE MOUTHWASH: A RANDOMIZED CLINICAL TRIAL.J Evid Based Dent Pract | PMID 40335199无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Midazolam with fentanyl for endobronchial ultrasound-guided transbronchial needle aspiration: a randomized, double-blind, phase III study.Lung Cancer | PMID 40345066无 PMCID | 2025-Jun | 0.95 | The record describes a phase III randomized trial but fails to meet key eligibility criteria: the study is not an oncology therapeutic trial (it focuses on procedural sedation for a diagnostic procedure), the drug intervention is not an anticancer therapy, and the primary endpoint is not a time-to-event efficacy endpoint. Therefore, it is excluded. | 待处理 |
| Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40349716无 PMCID | 2025-Jun | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| An Adult Population Pharmacokinetic Model to Simulate Subcutaneous Administration of a Fixed Dose of Furosemide in Adolescents with Heart Failure and Volume Overload.Clin Pharmacokinet | PMID 40360952PMC12159125 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study.Radiother Oncol | PMID 40379410无 PMCID | 2025-Jun | 0.95 | The study is a randomized Phase III trial in oncology (breast cancer) with original results. However, it is excluded because it does not involve a drug-containing intervention (it compares radiotherapy schedules) and its primary endpoint is a patient-reported normal tissue effect (safety/toxicity), not a time-to-event efficacy endpoint. | 待处理 |
| 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.Lancet Child Adolesc Health | PMID 40379431无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial.Lancet Neurol | PMID 40409314无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: a modeling analysis based on the CheckMate 9ER study.ESMO Open | PMID 40412006PMC12152543 | 2025-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Randomized Trial of Lung and Diaphragm Protective Ventilation in Children.NEJM Evid | PMID 40423397无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma.ESMO Open | PMID 40435872PMC12158521 | 2025-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:非 KM 图;Figure 3:非 KM 图;Figure 4:森林图/亚组分析图;Figure 5:非 KM 图。 | PMID 40446626PMC12166824 | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.Lancet Haematol | PMID 40447351无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40449498无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.ESMO Open已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图。 | PMID 40460679PMC12167086 | 2025-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials.Eur J Neurol | PMID 40462564PMC12134391 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neonatal BCG vaccination to prevent asthma: Results from the MIS BAIR randomized controlled trial.Pediatr Allergy Immunol | PMID 40464744PMC12136015 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:生活质量量表图;Figure 3:生活质量量表图。 | PMID 40472660PMC12173008 | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.Ann Hematol | PMID 40515823PMC12283465 | 2025-Jun | 0.85 | The report describes Phase III randomized trials of a drug intervention in humans, but the primary efficacy endpoint is patient-reported outcomes (PROs) and quality of life, not a time-to-event outcome. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.Curr Med Res Opin疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40528576无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease.Alzheimers Dement | PMID 40545559PMC12183105 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical efficacy of Shaomazhijing granules in the treatment of Tourette's syndrome: a randomized controlled trial.Hereditas | PMID 40450353PMC12125844 | 2025-May-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.Br J Surg | PMID 40474841无 PMCID | 2025-May-31 | 0.85 | The study is a randomized Phase III trial with a drug intervention, but the abstract does not report any time-to-event efficacy outcomes (like OS or PFS) with Kaplan-Meier or HR data. It focuses on surgical details and response rates, which are not the required primary/key secondary endpoint. | 待处理 |
| Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.N Engl J Med | PMID 40167274无 PMCID | 2025-May-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.N Engl J Med | PMID 40174237无 PMCID | 2025-May-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.BMC MedKM panel re-extraction failed | PMID 40437469PMC12121135 | 2025-May-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.Blood Adv | PMID 40085955PMC12143816 | 2025-May-27 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy.J Am Coll Cardiol | PMID 40099774无 PMCID | 2025-May-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: The FARES-II Multicenter Randomized Clinical Trial.JAMA | PMID 40156829PMC11955085 | 2025-May-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity: A Randomized Clinical Trial.JAMA | PMID 40274279PMC12022862 | 2025-May-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Modeling Disease Progression and Placebo Response in Huntington Disease: Insights From Enroll-HD and GENERATION HD1 Cohorts.Neurology | PMID 40315394PMC12057022 | 2025-May-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy.J Am Coll Cardiol | PMID 40398971无 PMCID | 2025-May-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study.BMJ Open | PMID 40436447PMC12121605 | 2025-May-27 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40349714无 PMCID | 2025-May-24 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Major depressive disorder in children and adolescents is associated with reduced hair cortisol and anandamide (AEA): cross-sectional and longitudinal evidence from a large randomized clinical trial.Transl Psychiatry | PMID 40413177PMC12103555 | 2025-May-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| HSK21542 in patients with postoperative pain: two phase 3, multicentre, double-blind, randomized, controlled trials.Nat Commun | PMID 40413233PMC12103582 | 2025-May-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis.Clin Exp Dermatol | PMID 39680511无 PMCID | 2025-May-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Psychometric validation of the EORTC QLQ-OES18 in patients with advanced or metastatic esophageal squamous cell carcinoma.J Patient Rep Outcomes | PMID 40397297PMC12095746 | 2025-May-21 | 0.90 | This is a quality-of-life/psychometric validation study derived from a Phase III randomized trial. It does not report the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) of the parent oncology trial. Therefore, it is excluded based on report_type and endpoint. | 待处理 |
| Associations of pretreatment emotional distress with adherence to therapy for patients with locally advanced rectal cancer: a post hoc analysis of the Chinese FOWARC phase 3 randomized clinical trial.BMC Med | PMID 40399932PMC12096767 | 2025-May-21 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40048691无 PMCID | 2025-May-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial.JAMA | PMID 40121537PMC11931425 | 2025-May-20 | 0.95 | The study is a randomized, phase III oncology trial in humans with original primary results. However, it is excluded because it lacks a drug-containing intervention (comparing diagnostic biopsy techniques) and does not report a time-to-event efficacy endpoint as defined. | 待处理 |
| High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.J Clin Oncol | PMID 40193822PMC12084015 | 2025-May-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.Circulation | PMID 40255182PMC12088884 | 2025-May-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE-TAVI AF Trial.J Am Heart Assoc | PMID 40371611PMC12184617 | 2025-May-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12.J Clin Endocrinol Metab | PMID 39243386PMC12086410 | 2025-May-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1.J Clin Endocrinol Metab | PMID 39378125PMC12086390 | 2025-May-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |